Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a case report

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1752-1947
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a case report ; volume:15 ; number:1 ; day:23 ; month:4 ; year:2021 ; pages:1-7 ; date:12.2021
Journal of medical case reports ; 15, Heft 1 (23.4.2021), 1-7, 12.2021

Creator
Kikuchi, Fumi
Saheki, Takanobu
Imachi, Hitomi
Kobayashi, Toshihiro
Fukunaga, Kensaku
Ibata, Tomohiro
Sato, Seisuke
Ban, Natsuki
Lyu, Jingya
Japar, Salimah
Murao, Koji
Contributor
SpringerLink (Online service)

DOI
10.1186/s13256-020-02656-7
URN
urn:nbn:de:101:1-2021061021134529694188
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:55 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Kikuchi, Fumi
  • Saheki, Takanobu
  • Imachi, Hitomi
  • Kobayashi, Toshihiro
  • Fukunaga, Kensaku
  • Ibata, Tomohiro
  • Sato, Seisuke
  • Ban, Natsuki
  • Lyu, Jingya
  • Japar, Salimah
  • Murao, Koji
  • SpringerLink (Online service)

Other Objects (12)

Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma

Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma

Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma

Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma

Metastatic Merkel cell carcinoma response to nivolumab

Metastatic Merkel cell carcinoma response to nivolumab

Low-dose nivolumab in advanced hepatocellular carcinoma

Low-dose nivolumab in advanced hepatocellular carcinoma

Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States

Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States

Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma

Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma

Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report

Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report

Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report

Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report

Related objects